technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases. We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of neuron cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation. The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval. On February 2011, NurOwn was granted Orphan Drug designation by the FDA. Over 20 publications in leading scientific journals demonstrating neuron mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.